AIM: To examine whether hepatitis C virus (HCV)-infected patients who carry hypercoagulable mutations suffer from increased rates of liver fibrosis. METHODS: We analyzed DNA samples of 168 HCV patients for three common hypercoagulable gene mutations: prothrombin 20210 (PT20210), factor V Leiden (FV Leiden) and methylene tetrahydrofolate reductase (MTHFR). The patients were consecutively recruited as part of the prospective "Fibroscore Study" in France. The effect of the various mutations on the rate of fibrosis was analyzed statistically and was correlated with epidemiological, clinical and biochemical data such as grade and stage of liver biopsies, patients' risk factors for liver cirrhosis, and timing of infection. RESULTS: Fifty two of the patients were categorized as "fast fibrosers" and 116 as "slow fibrosers"; 13% of the "fast fibrosers" carried the PT20210 mutation as compared with 5.5% of the "slow fibrosers", with an odds ratio of 4.76 (P = 0.033; 95% CI: 1.13-19.99) for "fast" liver fibrosis. Carriage of MTHFR or FV Leiden mutations was not associated with enhanced liver fibrosis. CONCLUSION: Carriage of the PT20210 mutation is related to an increased rate of liver fibrosis in HCV patients.
AIM: To examine whether hepatitis C virus (HCV)-infectedpatients who carry hypercoagulable mutations suffer from increased rates of liver fibrosis. METHODS: We analyzed DNA samples of 168 HCVpatients for three common hypercoagulable gene mutations: prothrombin 20210 (PT20210), factor V Leiden (FV Leiden) and methylene tetrahydrofolate reductase (MTHFR). The patients were consecutively recruited as part of the prospective "Fibroscore Study" in France. The effect of the various mutations on the rate of fibrosis was analyzed statistically and was correlated with epidemiological, clinical and biochemical data such as grade and stage of liver biopsies, patients' risk factors for liver cirrhosis, and timing of infection. RESULTS: Fifty two of the patients were categorized as "fast fibrosers" and 116 as "slow fibrosers"; 13% of the "fast fibrosers" carried the PT20210 mutation as compared with 5.5% of the "slow fibrosers", with an odds ratio of 4.76 (P = 0.033; 95% CI: 1.13-19.99) for "fast" liver fibrosis. Carriage of MTHFR or FV Leiden mutations was not associated with enhanced liver fibrosis. CONCLUSION: Carriage of the PT20210 mutation is related to an increased rate of liver fibrosis in HCVpatients.
Entities:
Keywords:
Hepatitis C virus; Hypercoagulation; Liver fibrosis; Prothrombin 20210
Authors: Z M Sthoeger; M Fogel; A Smirov; D Ergas; Y Lurie; D D Bass; D Geltner; S D Malnick Journal: Ann Rheum Dis Date: 2000-06 Impact factor: 19.103
Authors: M Harada; Y Fujisawa; S Sakisaka; T Kawaguchi; E Taniguchi; M Sakamoto; S Sumie; K Sasatomi; H Koga; T Torimura; T Ueno; K Gondo; H Yoshida; K Tanikawa; M Sata Journal: J Gastroenterol Date: 2000 Impact factor: 7.527
Authors: Luigi E Adinolfi; Diego Ingrosso; Giuseppe Cesaro; Amelia Cimmino; Maria D'Antò; Rosanna Capasso; Vincenzo Zappia; Giuseppe Ruggiero Journal: Hepatology Date: 2005-05 Impact factor: 17.425
Authors: Pierre-Yves Bochud; Tao Cai; Kathrin Overbeck; Murielle Bochud; Jean-François Dufour; Beat Müllhaupt; Jan Borovicka; Markus Heim; Darius Moradpour; Andreas Cerny; Raffaele Malinverni; Patrick Francioli; Francesco Negro Journal: J Hepatol Date: 2009-06-06 Impact factor: 25.083
Authors: K Zachou; C Liaskos; D K Christodoulou; M Kardasi; G Papadamou; N Gatselis; S P Georgiadou; E V Tsianos; G N Dalekos Journal: Eur J Clin Invest Date: 2003-02 Impact factor: 4.686
Authors: A J Freeman; G J Dore; M G Law; M Thorpe; J Von Overbeck; A R Lloyd; G Marinos; J M Kaldor Journal: Hepatology Date: 2001-10 Impact factor: 17.425
Authors: M Wright; R Goldin; S Hellier; S Knapp; A Frodsham; B Hennig; A Hill; R Apple; S Cheng; H Thomas; M Thursz Journal: Gut Date: 2003-08 Impact factor: 23.059
Authors: L G Poole; A Pant; K S Baker; A K Kopec; H M Cline-Fedewa; S E Iismaa; M J Flick; J P Luyendyk Journal: J Thromb Haemost Date: 2018-12-10 Impact factor: 5.824
Authors: Jessica P E Davis; Amy G Ogurick; Carrie E Rothermel; Min-Woong Sohn; Nicolas M Intagliata; Patrick G Northup Journal: Clin Appl Thromb Hemost Date: 2019 Jan-Dec Impact factor: 2.389
Authors: Martin Zalesak; Kevin Francis; Alex Gedeon; John Gillis; Kyle Hvidsten; Phyllis Kidder; Hong Li; Derek Martyn; Leslie Orne; Amanda Smith; Ann Kwong Journal: PLoS One Date: 2013-05-21 Impact factor: 3.240
Authors: Lauren G Poole; Asmita Pant; Holly M Cline-Fedewa; Kurt J Williams; Bryan L Copple; Joseph S Palumbo; James P Luyendyk Journal: Res Pract Thromb Haemost Date: 2020-06-25